Independent. No paid rankings. Our evidence grades are never for sale. Where a cosmetic or skincare product passes our review, we may link to it with a disclosed affiliate link. Reviewed weekly Editorial policy Newsletter

Home›Explore peptides›Semaglutide

Semaglutide

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 1 October 2026Funding No vendor payment

Yes, it works, and yes it's a real approved drug — sold under three different brand names for three different regulatory purposes. But "semaglutide" bought outside a licensed pharmacy on a valid prescription is a different legal situation entirely. FDA has proposed (not finalized) not to list it for 503B outsourcing-facility compounding.

Evidence grade A: what kinds of studies support the claims on this page, with limits. It is not a verdict on any product. How we grade

On this page

  1. What it is
  2. What the trial evidence shows
  3. The compounded/grey-market version
  4. Safety notes
  5. Canada: a genuine regulatory divergence
  6. Australia: a real gap between approval and availability
  7. United Kingdom: a licensed pill, a still-unscheduled NHS decision
  8. MASH: a second UK approval, and a NICE queue behind it
  9. NAION: a rare eye-disorder signal, and three different regulatory answers

In brief

Should you care? Yes — this is one of the most searched peptide names there is, and most of that search traffic is about the compounded, non-pharmacy version, not the approved drug the trials were actually run on.

The short version

  • Real drug, real trials. Multiple large, controlled human trials back it, for more than one indication.
  • Three brand names, three purposes: Ozempic (type 2 diabetes), Wegovy (chronic weight management), Rybelsus (oral, diabetes).
  • FDA has proposed not adding semaglutide to the 503B bulks list (which applies to outsourcing facilities); the proposal is not final. FDA says outsourcing facilities in most cases cannot compound from bulk substances unless the substance is listed or the drug is on the shortage list.
  • Canada already has a generic. A missed patent-maintenance fee let Health Canada authorize one years before the US is expected to.
  • The UK licensed an oral version in June 2026 — but it isn't an NHS drug yet. That's a separate decision, on a separate timeline, that hasn't started.
  • The UK also licensed it for liver disease in July 2026 — conditionally, and with no NHS route yet either. A NICE appraisal for that specific indication was already queued before the licence even landed.
  • A rare eye-disorder signal (NAION) is now labelled in the EU and UK, and flagged in Australia — three regulators acted on it before the FDA added an equivalent US warning.

Correction, 1 October 2026

This page previously said the compounded pathway “is closing,” that FDA proposed excluding semaglutide from “the list that let outsourcing pharmacies compound it during the shortage,” that FDA found “no sufficient clinical need once the shortage ended,” and that the proposal, if finalized, “closes the compounding pathway's legal basis.” FDA's notice does not tie its finding to the end of the shortage (it says shortages are not a clinical need) and does not address other compounding routes, so the wording now states what the notice proposes and that it is not final. FDA's 1 May 2026 Federal Register notice (91 FR 23431) is a proposal: it says FDA “tentatively finds no basis to conclude that there is a clinical need” and proposes not to include these substances on the 503B bulks list, and FDA's news release says the agency will consider comments before making a final determination. It applies to outsourcing facilities under section 503B only. No evidence grade changed.

Further changes, 1 October 2026: the opening summary and key point, the Library card and the legal-status tracker row no longer say the channel is “being formally closed” or that compounded supply is “restricted”; they say FDA has proposed, not finalized, not to list semaglutide on the 503B bulks list. The Federal Register notice and its comment-extension notice are now linked in the references. The “Not the same as the branded pen” box now uses FDA’s own wording on unapproved GLP-1 versions instead of “outside the approved-drug framework.”

What it is

Semaglutide is a GLP-1 receptor agonist — a once-weekly injectable (or once-daily oral) analog of human glucagon-like peptide-1, developed by Novo Nordisk. It slows gastric emptying and increases satiety, which is the basis for both its diabetes and its weight-management effects.

What the trial evidence shows

SUSTAIN-6 (Marso et al., N Engl J Med 2016, DOI 10.1056/NEJMoa1607141) found a 26% reduction in the composite of nonfatal heart attack, nonfatal stroke and cardiovascular death in high-cardiovascular-risk type 2 diabetes patients — the basis for a 2020 label expansion for cardiovascular risk reduction. STEP 1 (Wilding et al., N Engl J Med 2021, DOI 10.1056/NEJMoa2032183, PMID 33567185) — 1,961 adults without diabetes, 68 weeks — found mean weight loss of 14.9% on 2.4mg semaglutide versus 2.4% on placebo, the pivotal trial behind Wegovy's 2021 obesity approval. Rybelsus (oral) was approved in 2019 as the first oral GLP-1 medicine.

The compounded/grey-market version

During the 2022–2024 shortage, FDA allowed licensed compounding pharmacies to prepare semaglutide from bulk substance under sections 503A/503B. The shortage was declared resolved on 21 February 2025. On 30 April 2026, FDA announced a proposal (published in the Federal Register on 1 May 2026) not to include semaglutide — along with tirzepatide and liraglutide — on the 503B bulks list, tentatively finding no clinical need for outsourcing facilities to compound these drugs from bulk substances (Federal Register 2026-08552; FDA press release, 30 Apr 2026). The notice says shortages are not themselves a clinical need and that a separate provision covers drugs on FDA's shortage list. The comment period was later extended to 30 July 2026, and FDA has said it will consider comments before making a final determination. The proposal is not final and concerns outsourcing facilities under section 503B only; if finalized, those facilities in most cases could not compound these drugs from bulk substances unless the drug is on FDA's shortage list.

Not the same as the branded pen

Vials sold as "semaglutide" outside a pharmacy-dispensed prescription are not Ozempic, Wegovy or Rybelsus. FDA says unapproved versions of GLP-1 drugs, including semaglutide, do not undergo its review for safety, effectiveness and quality before they are marketed. See why RUO labelling doesn't change this.

Safety notes

The label carries a boxed warning for thyroid C-cell tumor risk, based on rodent carcinogenicity studies — this has not been established in humans, and the drug is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN2. Gastrointestinal side effects (nausea, vomiting) are common and are the most frequent reason people stop taking it. In SUSTAIN-6, a retinopathy complication signal appeared specifically in patients with pre-existing diabetic retinopathy — worth knowing if that applies to you, not a general population risk.

Canada: a genuine regulatory divergence

Everything above describes semaglutide's US status. Health Canada is a separate regulator, and for semaglutide specifically the two countries have genuinely diverged — not on safety or efficacy, but on patent administration. Novo Nordisk's Canadian compound patent required an annual maintenance fee (CAD $250, paid in 2018) with a late-payment option (CAD $450) after a missed 2019 renewal; the company let the one-year grace period lapse without paying, and the patent expired in Canada in 2020 as a result. That opened the door to generic competition years ahead of the US: Health Canada authorized Dr. Reddy's generic semaglutide injection on 28 April 2026 for the diabetes indication, then a weight-management-indication generic in June 2026 — making Canada the first G7 country with a generic semaglutide on the market. In the US, the FDA-listed core compound patent (US 8,129,343) isn't scheduled to expire until December 2031, with generic entry generally expected around 2032.

Why this matters beyond semaglutide

Health Canada and the FDA are independent regulators that can reach different timelines, and occasionally different conclusions entirely — this site's Atosiban page covers a drug approved in Canada and the EU that has never been approved in the US at all. Unless a page says otherwise, statements about "approval" or "legal status" on this site describe the US position specifically — see our standard.

Australia: a real gap between approval and availability

Australia's divergence is different in shape from Canada's: not a patent story, but a gap between a drug being approved and actually being on sale. The FDA approved Wegovy on 4 June 2021. Australia's TGA approved it in 2022 — but Wegovy was not actually available for purchase in Australia until August 2024, roughly three years after its US launch. During that gap, off-label prescribing of Ozempic (semaglutide's diabetes-indication brand, TGA-approved since 2019 and never approved for weight loss in either country) for weight loss surged in Australia — one analysis found a more than 400% increase in subsidized semaglutide prescriptions in a single year — and is widely credited as a driver of Australia's 2022–2023 Ozempic shortage, which left diabetes patients competing for supply with people using it off-label.

That availability gap has since evolved into a subsidy gap. Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recommended a PBS listing for Wegovy at its November 2025 meeting — for adults with established cardiovascular disease (a prior heart attack, stroke, or symptomatic peripheral arterial disease) and a BMI of 35 or higher — and Health Minister Mark Butler publicly confirmed the recommendation in January 2026. As of this review, that listing still hasn't happened: reporting indicates the government has pushed back on Novo Nordisk's pricing submission, and there's no confirmed date, though a listing sometime in 2026 or 2027 remains plausible. Until it lands, an unsubsidised Wegovy prescription in Australia runs roughly AUD $390–460 a month at the maintenance dose; a PBS listing would drop that to the standard $25 co-payment (or $7.70 with a concession card). For contrast, Ozempic is PBS-listed in Australia too — but only for type 2 diabetes, never weight loss — and Mounjaro (tirzepatide) has never been PBS-listed at all: PBAC recommended funding it in March 2026, but Eli Lilly rejected the government's price in April 2026 and walked away, though Lilly's CEO said in August 2026 he still wants a deal.

United Kingdom: a licensed pill, a still-unscheduled NHS decision

The MHRA licensed injectable Wegovy for weight management in 2021 — the same drug this page describes, in the form the pivotal STEP trials above were actually run on. On 11 June 2026, it licensed a once-daily tablet version of semaglutide for the same purpose: the first oral GLP-1 medicine approved in the UK specifically for weight management, for adults with a BMI of 30 or higher, or 27–29.9 with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity — patients start at a 1.5mg dose and titrate up to 25mg over several months. A licence only settles where a drug can legally be prescribed, not who pays for it — Novo Nordisk said at the time that it expected the tablet to reach patients through private prescription within weeks, and as of this review it is not an NHS-funded medicine.

Whether that changes, and when, is a separate decision made by a different body on its own timeline. NICE didn't recommend the injectable version of this drug for NHS use until March 2023 (TA875) — well over a year after the MHRA had already licensed it in 2021 — and reaching an actual local referral took longer again. NICE has listed a future appraisal of the tablet in its work programme (project ID6188), but as of this review that listing is still at the "awaiting development" stage, with no assessment timeline set and no guarantee of a positive recommendation once one begins; going by the injectable's own licence-to-recommendation gap, a realistic NHS decision sits at 2027 at the earliest.

That gap between a UK licence and an NHS place is the same pattern this page already describes for Canada and Australia — an approved medicine isn't automatically a covered one — and it sits alongside the tiered, BMI-based NHS rationing described in detail on tirzepatide's own NHS section for the injectable version of this drug class. Anyone offered the tablet by a UK clinic today is being offered a private prescription, not an NHS one, regardless of how the offer is worded.

MASH: a second UK approval, and a NICE queue behind it

The weight-management approvals above aren't the only ones semaglutide has picked up in the UK. On 3 July 2026, the MHRA licensed the injectable Wegovy — the same 2.4mg weekly drug this page already describes, not a new formulation — for a second, unrelated indication: metabolic dysfunction-associated steatohepatitis (MASH, the disease more familiar under its older name, NASH), specifically in adults with moderate-to-advanced liver fibrosis who don't yet have cirrhosis. It's a conditional marketing authorisation rather than a full one: the MHRA has said further confirmatory evidence is still required before it can convert to a standard licence, and it will review new data on the medicine at least once a year in the meantime. The approval rests on 72-week interim results from the ongoing Phase 3 ESSENCE trial; a second, longer part of that same trial, tracking liver-related clinical outcomes out to 240 weeks, isn't expected to read out until around 2029.

The FDA had already approved the identical indication in the US, through its own accelerated-approval pathway, on 15 August 2025 — nearly eleven months before the MHRA followed. That's a shorter gap than the multi-year approval-to-availability story this page describes for Australia above, but it's the same underlying pattern: the two regulators aren't reaching different conclusions here, just reaching them on different clocks.

And the "licensed isn't the same as funded" gap that applies to the oral tablet above applies here too, on an earlier timeline. NICE opened a separate technology appraisal for this specific indication — semaglutide for moderate-to-advanced liver fibrosis caused by MASH, project ID6458 — and published its final scope in November 2025, eight months before the MHRA had even licensed the drug for it. As of this review, that appraisal is still in development with no publication date set, and the MHRA's own announcement says plainly that patients with MASH cannot currently get semaglutide for this condition through the NHS. Anyone offered it today for liver disease specifically, rather than for weight management, is being offered a private prescription against the new licence, not an NHS one.

NAION: a rare eye-disorder signal, and three different regulatory answers

Since mid-2025, three separate regulators — the EU's EMA, the UK's MHRA, and Australia's TGA — have each formally reviewed a rare eye condition linked to semaglutide, and each reached a related but distinct conclusion on its own timeline. Non-arteritic anterior ischemic optic neuropathy (NAION) is a sudden, usually one-sided and largely irreversible loss of vision from reduced blood flow to the optic nerve — no treatment has been shown to improve the outcome once it happens, which is why all three reviews treated it as worth a formal safety process rather than a routine label tweak.

The EU acted first. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded its review on 6 June 2025, after examining non-clinical data, clinical-trial results, post-marketing reports and published epidemiological studies: NAION is a genuine, "very rare" side effect of semaglutide medicines specifically — Ozempic, Rybelsus and Wegovy — affecting up to 1 in 10,000 patients. The epidemiological studies behind that finding suggested people with type 2 diabetes taking semaglutide had roughly double the NAION risk of those who weren't, or about one additional case per 10,000 patient-years of treatment. PRAC's recommendation was a product-information update, not a prescribing restriction, and it applied to semaglutide specifically — not the wider GLP-1 class.

The UK reached a similar conclusion eight months later, through its own separate process. The MHRA's Drug Safety Update, published 5 February 2026, cites the same up-to-1-in-10,000 estimate and adds a UK-specific data point: as of August 2025, only three Yellow Card reports had linked semaglutide to NAION in the UK, against a drug taken by a very large number of people. Its instruction to prescribers is specific — refer anyone reporting sudden or partial vision loss for urgent ophthalmological assessment, and stop semaglutide if NAION is confirmed.

Australia's TGA went further, asking not just whether the signal was real but whether it was specific to semaglutide or shared across the whole drug class. Its Advisory Committee on Medicines (ACM) considered the question at its 3 October 2025 meeting and concluded the evidence may support the signal for semaglutide specifically, but not for dulaglutide or tirzepatide — the drug behind Mounjaro and Zepbound, covered on this site's own tirzepatide page. That distinction sits alongside a more complicated picture in the TGA's own numbers: when its class-wide safety alert was finally published on 23 July 2026 — nearly ten months after the ACM meeting — the national adverse-event database had logged 36 reports of the condition across the class: 23 for semaglutide, 10 for tirzepatide, 3 for liraglutide, and none for dulaglutide. A raw report count isn't the same as a statistically supported signal once drug exposure and reporting patterns are accounted for, which is presumably why the ACM's formal conclusion and the case tally don't line up one-to-one — but it's a real reason to read "not currently supported" for tirzepatide as provisional rather than a clean bill of health.

One country conspicuously absent from a formal label change here is the one the rest of this page describes: the FDA opened its own review of the same signal in July 2024, after a JAMA Ophthalmology study first reported the association — earlier than any of the three actions above — but as of this review had not added an equivalent NAION warning to Ozempic's US label. None of this is fully settled science, either: several systematic reviews and meta-analyses published through 2025 and 2026 report genuinely mixed results on whether semaglutide causes NAION at all, rather than a scientific consensus that regulators are simply implementing. What the EU, UK and Australian actions establish is narrower than "proven cause": a real, rare, now-labelled or flagged risk, with clear guidance on what to do if it happens, acted on in three jurisdictions before the FDA added anything equivalent.

What you can do next

References

  1. Marso et al., "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes," N Engl J Med 2016;375:1834-1844, DOI 10.1056/NEJMoa1607141.
  2. Wilding et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," N Engl J Med 2021;384:989-1002, DOI 10.1056/NEJMoa2032183, PMID 33567185.
  3. U.S. Food and Drug Administration, “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List,” news release, 30 April 2026. fda.gov; Federal Register 91 FR 23431 (1 May 2026), document 2026-08552. govinfo.gov; Federal Register document 2026-12937 (26 June 2026), extension of the comment period to 30 July 2026. govinfo.gov; FDA, Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy), 21 February 2025. fda.gov.
  4. Health Canada, "Canada becomes the first G7 country to approve a generic version of semaglutide," news release, 28 April 2026; "Canada approves first generic semaglutide for weight loss," news release, June 2026 (canada.ca).
  5. Reporting on the lapsed Canadian patent and its CAD $250/$450 maintenance-fee history: Bloomberg, "Novo's Ozempic Patent Expires Jan. 4 in Canada, But Generics Not Imminent," 23 December 2025; Science.org, "Novo Nordisk's Canadian Mistake."
  6. US semaglutide core compound patent (US 8,129,343), FDA Orange Book listing, expiry December 2031; generic entry commonly estimated around 2032 per patent-tracking analyses.
  7. FDA approval of Wegovy (semaglutide), 4 June 2021. TGA, Australian Public Assessment Report (AusPAR) for Wegovy, 4 September 2024; Wegovy availability in Australia from August 2024, per Novo Nordisk/TGA reporting.
  8. Reporting on Australia's 2022-2023 Ozempic shortage and off-label weight-loss prescribing surge: University of Sydney news commentary; SBS News; Monash University commentary, all discussing subsidized semaglutide prescription growth and the resulting shortage.
  9. Pharmaceutical Benefits Scheme, Public Summary Document, "Semaglutide – November 2025" (PBS ID a1121), pbs.gov.au — PBAC's recommended listing criteria and price/risk-sharing conditions; ABC News, 12 January 2026, on Health Minister Mark Butler's public confirmation of the recommendation; health.gov.au and Office of Impact Analysis materials on the PBS general co-payment ($25 from 1 January 2026) and concession co-payment ($7.70, frozen through 2029).
  10. ABC News, thelimbic.com, and Pharmacy Daily reporting on PBAC's March 2026 recommendation to fund tirzepatide (Mounjaro) and Eli Lilly's rejection of the government's reimbursement terms in April 2026, including a direct quote from Lilly Australia general manager Manny Simons; ABC News, 12 August 2026, on Eli Lilly CEO David Ricks's subsequent public comments still seeking a PBS deal.
  11. Medicines and Healthcare products Regulatory Agency (MHRA), licensing statement on oral semaglutide (Wegovy tablet) for weight management, 11 June 2026, reported directly by The Pharmaceutical Journal ("MHRA approves semaglutide oral tablets for weight loss," 11 June 2026) with the approved BMI/comorbidity criteria and dose-titration schedule (1.5mg to 25mg); corroborated by Novo Nordisk's own news release and Medscape UK. National Institute for Health and Care Excellence (NICE), Technology appraisal guidance TA875, "Semaglutide for managing overweight and obesity," published March 2023, against the MHRA's September 2021 licensing of injectable Wegovy, establishing the roughly 18-month licence-to-recommendation gap referenced above; NICE project page, "Oral semaglutide for managing overweight and obesity [ID6188]" (GID-TA11149), listed at the awaiting-development stage with no appraisal timeline set as of this review — nice.org.uk.
  12. MHRA/GOV.UK, "Semaglutide (Wegovy) approved to treat form of liver disease," press release, 3 July 2026, confirming the conditional marketing authorisation for adults with moderate-to-advanced liver fibrosis (without cirrhosis) caused by MASH, the requirement for further confirmatory evidence before full authorisation, the commitment to review new data at least annually, and that patients cannot currently get semaglutide for MASH on the NHS; independently corroborated by British Liver Trust and Liver UK ("New hope for people living with MASH as two treatments receive MHRA approval"), FirstWord Pharma, Pharmacy Business, and The Pharmaletter, all reporting the same approval date and terms.
  13. FDA, accelerated approval of Wegovy (semaglutide 2.4mg) for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis, 15 August 2025 — the same indication the MHRA licensed in the UK nearly eleven months later; Novo Nordisk press release and independent reporting (AJMC, Healio, Gastroenterology Advisor) on the same date and on the Phase 3 ESSENCE trial's 72-week interim histologic results as the approval basis, with the trial's longer Part 2 (liver-related clinical outcomes at 240 weeks) still ongoing and not expected to read out until around 2029.
  14. National Institute for Health and Care Excellence (NICE), "Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]" (GID-TA11477), final scope published November 2025, listed as in development with no appraisal publication date set as of this review — nice.org.uk.
  15. European Medicines Agency, "PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy," 6 June 2025 — ema.europa.eu; independently corroborated by the World Health Organization's own news item on the same review (27 June 2025), the Belgian Federal Agency for Medicines and Health Products (FAMHP) PRAC meeting-highlights page, and Italy's AIFA, which republished the EMA communication in full.
  16. Medicines and Healthcare products Regulatory Agency (MHRA), Drug Safety Update, "Semaglutide (Wegovy, Ozempic and Rybelsus): risk of non-arteritic anterior ischaemic optic neuropathy (NAION)," 5 February 2026 — gov.uk; independently corroborated by Community Pharmacy England and Prescriber (prescriber.org.uk), both reporting the same publication date, the up-to-1-in-10,000 estimate, and the three-UK-Yellow-Card-reports-as-of-August-2025 figure.
  17. Therapeutic Goods Administration (TGA), Advisory Committee on Medicines, "ACM meeting statement, Meeting 53, 3 October 2025," on its conclusion that the evidence may support the NAION signal for semaglutide but not dulaglutide or tirzepatide; TGA, "GLP-1 RAs and rare, but severe, eye disorders," safety alert published 23 July 2026, including its Database of Adverse Event Notifications tally (36 total reports: 23 semaglutide, 10 tirzepatide, 3 liraglutide, none dulaglutide) — both tga.gov.au; independently corroborated by ABC News, "TGA issues warning over GLP-1-based drugs' potential to cause rare eye disorder," 24 July 2026, and by Diabetes Australia, Optometry Australia and RACGP's newsGP, all reporting the same publication date and case counts.
  18. FDA safety review of semaglutide and NAION opened following Hathaway et al., "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide," JAMA Ophthalmology, 3 July 2024; multiple 2026 regulatory-tracking summaries note the FDA had not added an equivalent NAION label warning to Ozempic as of this review, in contrast to the EU, UK and Australian actions above. On the mixed underlying evidence base: Khani et al., "Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis," J Clin Pharmacol 2026, and a separate systematic review and narrative synthesis on semaglutide and NAION (PMC, 2026), both describing observational studies with genuinely mixed and sometimes conflicting findings on causality.